stockrow
Friday 6 November 2026
Export VTGN’s income statement to Excel — free account
VistaGen Therapeutics, Inc.
VTGN Healthcare Biotechnology
VistaGen Therapeutics, Inc.’s revenue for fiscal 2026 (year ended March 2026) was $1.3 million, up 161.1% from fiscal 2025.
- Revenue
- +504.9%
- EPS
- +36.2%
- Free cash flow
- +22.2%
Quarter to June 2026, against a year earlier
0.17
0.00
0.00%
Follow VTGN
Alert me
VistaGen Therapeutics, Inc. (VTGN) P/E ratio
VistaGen Therapeutics, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2026 | 0.0× | — |
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2017 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 21 more quarters | Free account |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| LEXX Lexaria Bioscience Corp. compare | n/m |
| MTVA MetaVia Inc. compare | n/m |
| NKGN NKGen Biotech, Inc. compare | n/m |
| CLGN CollPlant Biotechnologies Ltd. Sponsored ADR compare | n/m |
| SNGX Soligenix Inc. compare | n/m |
| LTRN Lantern Pharma Inc. compare | n/m |
| VTGN VistaGen Therapeutics, Inc. | n/m |
| TOVX Theriva Biologics, Inc. compare | n/m |
| ACTU Actuate Therapeutics, Inc. compare | n/m |
| Biotechnology industry median | 10.3× |
| Healthcare sector median | 25.2× |
| Market median | 17.9× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)